<DOC>
	<DOCNO>NCT00027833</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Tetanus toxoid may make tumor cell sensitive chemotherapy vaccine therapy . PURPOSE : Randomized phase II trial study effectiveness chemotherapy vaccine therapy without tetanus toxoid compare chemotherapy alone treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Vaccine Therapy Chemotherapy With Without Tetanus Toxoid Compared With Chemotherapy Alone Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety ALVAC-CEA-B7.1 vaccine chemotherapy , without tetanus toxoid , vs chemotherapy alone patient metastatic colorectal adenocarcinoma . - Determine whether tetanus toxoid enhance immune response patient treat vaccine chemotherapy . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive prim dose tetanus toxoid . Beginning 2 week later , patient receive tetanus toxoid ALVAC-CEA-B7.1 vaccine subcutaneously ( SC ) weekly 3 week . Two week third vaccine administration , patient receive tetanus toxoid ALVAC-CEA-B7.1 vaccine SC day 1 irinotecan IV 90 minute , leucovorin calcium IV , fluorouracil IV day 1 , 8 , 15 , 22 . Treatment repeat every 6 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive ALVAC-CEA-B7.1 vaccine chemotherapy arm I . - Arm III : Patients receive chemotherapy arm I . After completion chemotherapy , patient partial complete response may receive ALVAC-CEA-B7.1 vaccine SC weekly week 1-3 6 . PROJECTED ACCRUAL : A total 90 patient ( 30 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colorectal adenocarcinoma No clinically active CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 6 month Hematopoietic : Lymphocyte count least 1,000/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST/ALT le 3 time ULN ( 5 time ULN liver metastasis present ) Alkaline phosphatase less 3 time ULN ( 5 time ULN liver metastasis present ) No hepatocellular dysfunction No cirrhosis Renal : Creatinine le 2.5 mg/dL Cardiovascular : No uncontrolled coronary artery disease No symptomatic congestive heart failure Pulmonary : No uncontrolled chronic obstructive lung disease Gastrointestinal : No unsolved bowel obstruction subobstruction No uncontrolled Crohn 's disease No ulcerative colitis No concurrent chronic diarrhea Immunologic : HIV negative No immunocompromised patient No diagnosis alter immune function , include : Lupus erythematosus Sjogren 's syndrome Scleroderma Myasthenia gravis Goodpasture 's disease Addison 's disease Hashimoto 's thyroiditis Active Graves ' disease No known allergy egg product neomycin No prior adverse reaction tetanus toxoidcontaining vaccine Other : No significant comorbid medical function No uncontrolled infection No unstable diabetes mellitus No uncontrolled thyroid function abnormalities No malignancy within past 5 year except basal cell carcinoma adequately treat carcinoma situ cervix No medical illness mental status would preclude study participation No prior severe toxicity adjuvant chemotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior CEAdirected immunotherapy No concurrent immunotherapy Chemotherapy : At least 6 month since prior adjuvant chemotherapy No prior chemotherapy metastatic disease No concurrent chemotherapy Endocrine therapy : No concurrent daily use systemic steroid No concurrent nonsubstitutional hormonal therapy Radiotherapy : No prior radiotherapy 50 % nodal group No concurrent radiotherapy except palliative purpose involve less 20 % bone marrow reserve Surgery : No prior major organ allograft Recovered prior surgery Other : At least 28 day since prior investigational product No concurrent investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>